The marker for determining efficacy of hepatitis B vaccination is:
**Core Concept**
The efficacy of hepatitis B vaccination is assessed by measuring the antibody response against the hepatitis B surface antigen (HBsAg). This is crucial for ensuring that the vaccine provides adequate protection against hepatitis B virus (HBV) infection.
**Why the Correct Answer is Right**
The correct marker for determining the efficacy of hepatitis B vaccination is the antibody to hepatitis B surface antigen (anti-HBs). The presence of anti-HBs indicates that the vaccine has elicited a protective immune response, which is essential for preventing HBV infection. The anti-HBs antibody is produced in response to the HBsAg antigen present in the vaccine, and its levels can be measured to assess the vaccine's efficacy.
**Why Each Wrong Option is Incorrect**
* **Option A:** This option is incorrect because it does not directly relate to the assessment of hepatitis B vaccine efficacy. Antibodies to hepatitis B core antigen (anti-HBc) are typically associated with past or current HBV infection, rather than vaccination.
* **Option B:** This option is incorrect because it is not a specific antibody that is used to measure the efficacy of hepatitis B vaccination. The term "hepatitis B antibodies" is too broad and nonspecific.
* **Option D:** This option is incorrect because it is not a marker for determining the efficacy of hepatitis B vaccination. The presence of HBsAg in a person's blood typically indicates an active HBV infection, rather than vaccination.
**Clinical Pearl / High-Yield Fact**
It's essential to note that the presence of anti-HBs antibodies can wane over time, even in individuals who have received the hepatitis B vaccine. This is why booster doses may be recommended for certain individuals, such as healthcare workers or individuals with high-risk occupations.
**Correct Answer: C. Anti-HBs**